{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Safety and tolerability will be assessed by clinical review of all relevant parameters, including dose limiting toxicities. Toxicity type and severity will be summarized by frequency tables. Maximum tolerated dose defined as the highest dose level in which patients have been treated with less than 2 instances of dose-limiting toxicity (Phase I)","groups":[{"description":"5 mg of Pomalidomide Daily days 1 - 21. 40 mg Dexamethasone On days 1, 8. 15, 22. 4mcg/kg of Zarxio (G-CSF) Days 22- 28.","id":"OG000","title":"Maximum Tolerated Dose (MTD)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 days","title":"Maximum Tolerated Dose (MTD) (Phase I)","type":"PRIMARY","unitOfMeasure":"mg"}